4.6 Article

Reconsidering 'minimal risk' to expand the repertoire of trials with waiver of informed consent for research

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Immunology

How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols

Archana Asundi et al.

Summary: In the early stages of the COVID-19 pandemic, institutions quickly implemented emerging information into clinical practice, favoring administering some form of therapy over clinical trial referral. Themes of urgent protocol development, rapid updates, and improving processes for clinical care were identified as critical aspects of translating evidence into practice.

OPEN FORUM INFECTIOUS DISEASES (2021)

Article Medicine, Research & Experimental

Implementation of documented and written informed consent for clinical trials of communicable diseases: Lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial

Patricia Woods et al.

Summary: In order to obtain regulatory-compliant informed consent during the COVID-19 pandemic, researchers have identified and pilot-tested various processes such as face-to-face, phone or video chat consent, integration of consent forms into software, and secure software programs with electronic signature. These processes are time-intensive and require coordination between multiple parties, leading to a need for evaluating efficiency and potentially modifying consent procedures.

CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2021)

Article Medicine, General & Internal

Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence

Victoria L. Bartlett et al.

JAMA NETWORK OPEN (2019)

Article Pharmacology & Pharmacy

Response-adaptive clinical trials: case studies in the medical literature

Andrew P. Grieve

PHARMACEUTICAL STATISTICS (2017)

Article Health Care Sciences & Services

Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory

Kevin P. Weinfurt et al.

BMC MEDICAL RESEARCH METHODOLOGY (2017)

Article Health Care Sciences & Services

Partnering with health system operations leadership to develop a controlled implementation trial

Mark S. Bauer et al.

IMPLEMENTATION SCIENCE (2016)

Editorial Material Medicine, General & Internal

Convergence of Implementation Science, Precision Medicine, and the Learning Health Care System A New Model for Biomedical Research

David A. Chambers et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Review Medicine, General & Internal

Pragmatic Trials

Ian Ford et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Medicine, Research & Experimental

The Food and Drug Administration and pragmatic clinical trials of marketed medical products

Monique L. Anderson et al.

CLINICAL TRIALS (2015)

Article Medicine, Research & Experimental

Clinical trials in crisis: Four simple methodologic fixes

Andrew J. Vickers

CLINICAL TRIALS (2014)

Article Medicine, General & Internal

Informed Consent, Comparative Effectiveness, and Learning Health Care

Ruth R. Faden et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Review Medicine, General & Internal

The answer is 17 years, what is the question: understanding time lags in translational research

Zoe Slote Morris et al.

JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2011)

Article Critical Care Medicine

Randomized, controlled trials as minimal risk: An ethical analysis

Marilyn C. Morris et al.

CRITICAL CARE MEDICINE (2007)